Remove Clinic Remove Diagnose Remove Disease Remove Radiopharmaceuticals
article thumbnail

Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma

Imaging Technology

a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, is pleased to announce that the first subject has been dosed in its Phase 1 study of 68Ga-R8760. Gary Hammer , M.D.,

article thumbnail

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

Imaging Technology

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Evidence grows for use of amyloid PET in China

AuntMinnie

Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. of patients, noted lead author Ke-Liang Chen, MD, a neurologist at Fudan University. “In

PET Scan 104
article thumbnail

University Hospitals Cleveland, Siemens Healthineers in New Alliance to Improve Oncology, Cardiovascular and Neurovascular Care for Patients

Imaging Technology

milla1cf Tue, 05/14/2024 - 12:45 May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on their 40-year history of clinical and research collaboration. tesla and 3T scanners. Separately, Varian, a Siemens Healthineers company, will provide linear accelerators.

Hospital 116
article thumbnail

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. FDA, as well as on the Phase 3 clinical trial results published recently in the Journal of Urology and European Urology. Chief Executive Officer of the Company. “We

article thumbnail

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We

article thumbnail

Widespread Staff Shortages Exacerbate Pressures Facing Radiation Oncology Clinics; ASTRO Advocacy Day Calls for Action

Imaging Technology

milla1cf Tue, 05/23/2023 - 11:36 May 23, 2023 — More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages , according to a new national survey from the American Society for Radiation Oncology ( ASTRO ). Radiation oncologists from across the country are in Washington, D.C. in the past three decades.